NCT04220684 - Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

October 22, 2024

Study Completion Date

December 31, 2025

Conditions

Allogeneic Stem Cell Transplant RecipientBlasts 10 Percent or More of Bone Marrow Nucleated CellsRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine Hydrochloride

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Given via infusion

Trial Locations (2)

24344

Oregon Health & Science University, Portland

43210

Ohio State University Comprehensive Cancer Center, Columbus